CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 568 enrolled
Drug / intervention
Herpes zoster vaccine (GSK 1437173A) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01767467
NCT01767467Phase 3Completed
CompareCT.gov

Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 18 Years and Older With Haematologic Malignancies

GlaxoSmithKline·interventional·Posted Jan 14, 2013·Updated Jun 6, 2018

In Brief

A Phase 3 clinical trial evaluating Herpes zoster vaccine (GSK 1437173A) and Placebo for Herpes Zoster. Completed, enrolled 568 participants across 86 sites in 21 countries.

Detailed Summary

The purpose of this study is to evaluate the safety and immunogenicity of GSK Biologicals' vaccine GSK1437173A in subjects aged 18 years and older with blood cancers. The study will evaluate safety-related events and antibody and cellular immune responses to the study vaccine, as compared to placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHerpes Zoster
CountriesAustralia, Belgium, Canada, Czechia, Finland, France, Hong Kong, Italy, New Zealand, Pakistan, Panama, Poland, Russia, Singapore, South Korea, Spain, Sweden, Taiwan, Turkey (Türkiye), United Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 14, 2013
Enrollment StartMar 1, 2013
Primary CompletionJan 7, 2016
Study CompletionJan 6, 2017
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 13.5 years ago

Interventions

Herpes zoster vaccine (GSK 1437173A)biological

2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm. Dose 1 administered at Day 0. Dose 2 administered 1-2 months post Dose 1.

Placebodrug

2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm. Dose 1 administered at Day 0. Dose 2 administered 1-2 months post Dose 1.